Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.43 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.43 |
| ▸ | MLYCD | O95822 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.41 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.40 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.40 |
| ▸ | LIPE | Q05469 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14868314 | 0.85 | AOC3 (0.49) | TAAR1AOC3NPY5RABCC1MLYCD | |
| SCHEMBL13584266 | 0.84 | SIGMAR1 (0.45) | TAAR1AOC3NPY5RABCC1SIGMAR1 | |
| SCHEMBL17198853 | 0.84 | TAAR1 (0.51) | TAAR1AOC3SIGMAR1 | |
| SCHEMBL14868329 | 0.84 | TAAR1 (0.46) | TAAR1AOC3NPY5RABCC1MLYCD | |
| Hydrochloric Acid SCHEMBL1939030 | 0.84 | AOC3 (0.47) | TAAR1AOC3NPY5RABCC1MLYCD | |
| Hydrochloric Acid SCHEMBL13584552 | 0.83 | SIGMAR1 (0.44) | TAAR1AOC3NPY5RABCC1SIGMAR1 | |
| SCHEMBL18624782 | 0.83 | TAAR1 (0.42) | TAAR1AOC3NPY5RABCC1MLYCD | |
| Hydrochloric Acid SCHEMBL28482320 | 0.83 | TAAR1 (0.44) | TAAR1AOC3NPY5RABCC1MLYCD | |
| SCHEMBL17198794 | 0.81 | AOC3 (0.51) | TAAR1AOC3SIGMAR1 | |
| SCHEMBL13641355 | 0.77 | NPC1 (0.58) | AOC3ABCC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3131877-B1 | BIGUANIDE COMPOUNDS | IMMUNOMET THERAPEUTICS INC (US) | 2023-07-19 | — | — | EP | disclosed |
| US-20170073331-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | IMMUNOMET THERAPEUTICS INC. (US) | 2017-03-16 | — | — | US | disclosed |
| US-20170073331-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | IMMUNOMET THERAPEUTICS INC. (US) | 2017-03-16 | — | — | US | disclosed |
| WO-2015160220-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | HANALL BIOPHARMA CO., LTD. (KR) | 2015-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170073331-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | PC, TFAM, PCK2 | TAAR1 4576/4885AOC3 3138/4885NPY5R 3786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.